Role of diffusion-weighted imaging in evaluating therapeutic efficacy after transcatheter arterial chemoembolization for hepatocellular carcinoma

Oncology Reports

Volumn 24, Issue 3, 2010, Pages 727-732

  Kubota, Kei ^a   Yamanishi, Tomoaki ^a   Itoh, Satoshi ^a   Murata, Yoriko ^a   Miyatake, Kana ^a   Yasunami, Hiroaki ^a   Morio, Kazuo ^a   Hamada, Norihiko ^a   Nishioka, Akihito ^a   Ogawa, Yasuhiro ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Diffusion weighted imaging; Hepatocellular carcinoma; Liver neoplasm; Magnetic resonance imaging; Transcatheter arterial chemoembolization

Indexed keywords

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL EMBOLISM; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TOMOGRAPHY, SPIRAL COMPUTED; TREATMENT OUTCOME;

EID: 77956299582     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000914     Document Type: Article

References (36)

1. No authors listed: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28: 751-755, 1998.
2. Yu YQ, Xu DB, Zhou XD, Lu JZ, Tang ZY and Mack P: Experience with liver resection after hepatic arterial chemo-embolization for hepatocellular carcinoma. Cancer 71: 62-65, 1993. (Pubitemid 23019282)
3. Di Carlo V, Ferrari G, Castoldi R, et al: Pre-operative chemo-embolization of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology 45: 1950-1954, 1998.
4. Llovet JM, Real MI, Montana X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734-1739, 2002.
5. Kim T, Murakami T, Takahashi S, Hori M, Tsuda K and Nakamura H: Diffusion-weighted single-shot echoplanar MR imaging for liver disease. AJR 173: 393-398, 1999. (Pubitemid 29347365)
6. Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B and Menu Y: Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 226: 71-78, 2003.
7. Nasu K, Kuroki Y, Nawano S, et al: Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 239: 122-130, 2006.
8. Chen CY, Li CW, Kuo YT, et al: Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants - initial experience. Radiology 239: 448-456, 2006.
9. Kamel IR, Bluemke DA, Eng J, et al: The role of functional MR imaging in the assessment of tumor response after chemo-embolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 17: 505-512, 2006. (Pubitemid 44318722)
10. Koh DM and Collins DJ: Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR 188: 1622-1635, 2007.
11. Koh DM, Scurr E, Collins D, et al: Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR 188: 1001-1008, 2007.
12. Moffat BA, Hall DE, Stojanovska J, et al: Diffusion imaging for evaluation of tumor therapies in preclinical animal models. MAGMA 17: 249-259, 2004. (Pubitemid 40362308)
13. Moffat BA, Chenevert TL, Lawrence TS, et al: Functional diffusion map: a non-invasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 102: 5524-5529, 2005.
14. Imaeda T, Yamawaki Y, Seki M, et al: Lipiodol retention and massive necrosis after lipiodol-chemoembolization of hepatocellular carcinoma: correlation between computed tomography and histopathology. Cardiovasc Intervent Radiol 16: 209-213, 1993.
15. Takayasu K, Arii S, Matsuo N, et al: Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR 175: 699-704, 2000.
16. Kubota K, Hisa N, Nishikawa T, et al: Evaluation of hepatocellular carcinoma after treatment with transcatheter arterial chemoembolization: comparison of Lipiodol-CT, power Doppler sonography and dynamic MRI. Abdom Imaging 26: 184-190, 2001. (Pubitemid 32187124)
17. Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171, 2002.
18. Bruix J, Llovet JM, Castells A, et al: Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27: 1578-1583, 1998. (Pubitemid 28264682)
19. Pelletier G, Ducreux M, Gay F, et al: Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 29: 129-134, 1998.
20. Ernst O, Sergent G, Mizrahi D, Delemazure O, Paris JC and L'Hermine C: Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. AJR 172: 59-64, 1999. (Pubitemid 29028431)
21. Chung JW, Park JH, Han JK, et al: Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198: 33-40, 1996.
22. Chan AO, Yuen MF, Hui CK, Tso WK and Lai CL: A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 94: 1747-1752, 2002.
23. Kim HC, Kim AY, Han JK, et al: Hepatic arterial and portal venous phase helical CT in patients treated with transcatheter arterial chemoembolization for hepatocellular carcinoma: added value of unenhanced images. Radiology 225: 773-780, 2002.
24. Murakami T, Nakamura H, Tsuda K, et al: Treatment of hepatocellular carcinoma by chemoembolization: evaluation with 3DFT MR imaging. AJR 160: 295-299, 1993. (Pubitemid 23059216)
25. De Santis M, Alborino S, Tartoni PL, Torricelli P, Casolo A and Romagnoli R: Effects of lipiodol retention on MRI signal intensity from hepatocellular carcinoma and surrounding liver treated by chemoembolization. Eur Radiol 7: 10-16, 1997.
26. Rubin JM, Bude RO, Carson PL, Bree RL and Adler RS: Power Doppler US: a potentially useful alternative to mean frequency-based color Doppler US. Radiology 190: 853-856, 1994. (Pubitemid 24071059)
27. Kubota K, Hisa N, Fujiwara Y, Fukumoto M, Yoshida D and Yoshida S: Evaluation of the intratumoral vasculature of hepatocellular carcinoma by power Doppler sonography: advantages and disadvantages versus conventional color Doppler sonography. Abdom Imaging 25: 172-178, 2000.
28. Chenevert TL, McKeever PE and Ross BD: Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 3: 1457-1466, 1997.
29. Einarsdóttir H, Karlsson M, Wejde J and Bauer HC: Diffusion-weighted MRI of soft tissue tumours. Eur Radiol 14: 959-963, 2004. (Pubitemid 38787237)
30. Geschwind JF, Artemov D, Abraham S, et al: Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis. J Vasc Interv Radiol 11: 1245-1255, 2000.
31. Yuan YH, Xiao EH, Liu JB, et al: Characteristics and pathological mechanism on magnetic resonance diffusion-weighted imaging after chemoembolization in rabbit liver VX-2 tumor model. World J Gastroenterol 13: 5699-5706, 2007.
32. Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW and Taouli B: Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR 193: 1044-1052, 2009.
33. Yuan Z, Ye XD, Dong S, Xu LC, Xu XY, Liu SY and Xiao XS: Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma. Eur J Radiol (In press).
34. Goshima S, Kanematsu M, Kondo H, Yokoyama R, Tsuge Y, Shiratori Y, Onozuka M and Moriyama N: Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator? J Magn Reson Imaging 27: 834-839, 2008.
35. Youn BJ, Chung JW, Son KR, et al: Diffusion-weighted MR: therapeutic evaluation after chemoembolization of VX-2 carcinoma implanted in rabbit liver. Acad Radiol 15: 593-600, 2008.
36. Koh DM, Takahara T, Imai Y and Collins DJ: Practical aspects of assessing tumors using clinical diffusion-weighted imaging in the body. Magn Reson Med Sci 6: 211-224, 2007.